The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and commercialization The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular AP's BPC 157 peptide warning skips every doctor who disagrees Seattle Red FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate AJMC